J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Quantification of HIV in semen: correlation with antiviral treatment and immune status
Pietro Vernazza,Bruce L. Gilliam,John R. Dyer,Susan A. Fiscus,Joseph J. Eron,Andreas C. Frank,Myron S. Cohen +6 more
TL;DR: The study showed that the concentration of HIV in semen, which was likely to be correlated with HIV infectivity, was a function of the immune status of the HIV‐infected individual and suggested that antiviral therapy may have reduced the concentration in semen.
Journal ArticleDOI
Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada
Keri N. Althoff,Stephen J. Gange,Marina B. Klein,John T. Brooks,Robert S. Hogg,Ronald J. Bosch,Michael A. Horberg,Michael S. Saag,Mari M. Kitahata,Amy C. Justice,Kelly A. Gebo,Joseph J. Eron,Sean B. Rourke,M. John Gill,Benigno Rodriguez,Timothy R. Sterling,Liviana Calzavara,Steven G. Deeks,Jeffrey N. Martin,Anita Rachlis,Sonia Napravnik,Lisa P. Jacobson,Gregory D. Kirk,Ann C. Collier,Constance A. Benson,Michael J. Silverberg,Margot Kushel,James J. Goedert,Rosemary G. McKaig,Stephen E. Van Rompaey,Jinbing Zhang,Richard D. Moore +31 more
TL;DR: CD4 count at first presentation for HIV care has increased annually over the past 11 years but has remained <350 cells/mm(3), which suggests the urgent need for earlier HIV diagnosis and treatment.
Journal ArticleDOI
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
J. Michael Kilby,Jacob Lalezari,Joseph J. Eron,Margrit Carlson,Calvin J. Cohen,Roberto C. Arduino,Jeffrey Goodgame,Joel E. Gallant,Paul A. Volberding,Paul A. Volberding,Robert L. Murphy,Fred T. Valentine,Michael S. Saag,Emily L. Nelson,Prakash R. Sista,Alex Dusek +15 more
TL;DR: Dose-related decreases in viral load were observed, with a maximum mean reduction from baseline of 1.6 log(10) copies/ml (p< 0.001) seen in the 100 mg bid SC group.
Journal ArticleDOI
3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
Roy M. Gulick,John W. Mellors,Diane V. Havlir,Joseph J. Eron,Anne R. Meibohm,Jon H. Condra,Fred T. Valentine,Deborah McMahon,Charles J. Gonzalez,Leslie Jonas,Emilio A. Emini,Chodakewitz Jeffrey A,Robin Isaacs,Douglas D. Richman +13 more
TL;DR: Results are presented after 3 years of follow-up in patients who received three-drug therapy with indinavir, zidovudine, and lamivudine in a previously reported study on HIV-infected adults.
Journal ArticleDOI
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.
Alison G. Abraham,Gypsyamber D'Souza,Yuezhou Jing,Stephen J. Gange,Timothy R. Sterling,Michael J. Silverberg,Michael S. Saag,Sean B. Rourke,Anita Rachlis,Sonia Napravnik,Richard D. Moore,Marina B. Klein,Mari M. Kitahata,Gregory D. Kirk,Robert S. Hogg,Nancy A. Hessol,James J. Goedert,M. John Gill,Kelly A. Gebo,Joseph J. Eron,Eric A. Engels,Robert Dubrow,Heidi M. Crane,John T. Brooks,Ronald J. Bosch,Howard D. Strickler +25 more
TL;DR: Elevated incidence of invasive cervical cancer is found in HIV-infected compared with -uninfected women, and these rates increased with immunosuppression, and the relationship of HIV infection and CD4+ T-cells with risk of ICC was assessed using age-adjusted Poisson regression models and standardized incidence ratios.